

Supplementary Table**Table S1****Association of clinicopathological parameters and expression of CD105 in 33 patients with choriocarcinoma (Mann-Whitney U test).**

	Cytotrophoblasts		Intermediate trophoblasts		Syncytiotrophoblasts	
	n	<i>P</i>	n	<i>P</i>	n	<i>P</i>
Age						
≤35	19	0.912	22	0.206	20	0.977
>35	8		11		7	
Preoperative β-hCG (mIU/mL)						
≤5	18	0.260	24	0.977	17	0.671
>5	9		9		10	
Preoperative chemotherapy cycles						
≤4	14	0.135	19	0.343	13	0.166
>4	13		14		14	
Relapse						
NO	20	0.038	25	0.068	21	0.021
YES	7		8		6	

Table S2**Association of clinicopathological parameters and expression of BMP9 in 33 patients with choriocarcinoma (Mann-Whitney U test).**







	Cytotrophoblasts		Intermediate trophoblasts		Syncytiotrophoblasts	
	n	<i>P</i>	n	<i>P</i>	n	<i>P</i>
Age						
≤35	19	0.774	22	0.373	20	0.588
>35	8		11		7	
Preoperative β-hCG (mlu/mL)						
≤5	18	0.176	24	0.231	17	0.141
>5	9		9		10	
Preoperative chemotherapy cycles						
≤4	14	0.790	19	0.527	13	0.728
>4	13		14		14	
Relapse						
NO	20	0.045	25	0.037	21	0.002
YES	7		8		6	

Table S3**Correlation between CD105 and BMP9 expression (Spearman test).**

Cell type	<i>r</i>	<i>P</i>
Cytotrophoblasts	0.461	0.018
Intermediate trophoblasts	0.046	0.801
Syncytiotrophoblasts	0.531	0.004

Supplementary Figure legend

Supplementary Fig. (A) Cell viability by a CCK8 assay after treating with increasing concentrations of BMP9 in JEG-3/CD105 OE and JEG-3/shCD105 cells (*, $P < 0.05$, Student's t-test). (B) Cell viability and IC_{50} values for MTX and FUDR with respect to JEG-3/CD105 OE and JEG-3/shCD105 cells after BMP9 treatment (10 ng/ml; *, $P < 0.05$, Student's t-test).



		CD105 OE		shCD105	
		FUDR	MTX	FUDR	MTX
IC50 µg/ml	BMP9+5%FBS	9.044	11.763	1.351	0.195
	5%FBS	3.242	1.793	0.883	0.122